OPEN ACCESS pISSN 2234-3806
eISSN 2234-3814

Fig. 1.

Download original image

Fig. 1.

Biological disease-modifying anti-rheumatic drugs (bDMARDs) are associated with immunogenicity, leading to the development of anti-drug antibodies that affect drug efficacy and may affect drug safety and tolerability. The development of anti-drug antibodies seems to be influenced by multiple risk factors and may be modulated by the concomitant use of conventional synthetic DMARDs (cs-DMARDs).

Ann Lab Med 2020;40:101~113 https://doi.org/10.3343/alm.2020.40.2.101

© Ann Lab Med